FindTrial
Sign In

To assess the therapeutic efficacy of Seer (Allium sativum) in Atherosclerosis in patients of Type 2 Diabetes Mellitus

Therapeutic evaluation of Seer (Allium sativum) in Atherosclerosis in patients of Type 2 Diabetes Mellitus An open randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/047805
Enrollment
60
Registered
2022-12-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I709- Other and unspecified atherosclerosis

Interventions

Intervention1: Seer (Allium sativum): Dried bulb of Seer (powder form) will be given in the form of capsule- 750 mg each capsule, in the dosage of 2 capsules twice daily orally, after meal, for 3 mo

Sponsors

Department of Moalejat Faculty of Unani Medicine AKTC Aligarh Muslim University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients in age group of 30-65 years. Patients of either sex. Controlled case of Type 2 Diabetes Mellitus either by drug or life style modification. Fasting blood sugar Patients able to participate in the study to follow the instructions Subjective Parameters: Patients showing any one of the following symptoms will be suspected and has to go further screening through Diabetes Risk Profiler and Investigations; 1.Increasing body weight 2.Fatigue 3.Exertional dyspnea 4.Xanthelasma 5.Corneal arcus 6.Controlled Essential Hypertension Objective Parameters: 1.Arterial stiffness index to be evaluated with Diabetes Risk Profiler (Borderline, Mild & Moderate Arterial stiffness) 2.Fasting blood sugar 3.Lipid profile: Any two of the following 1.Total Cholesterol: 200-300 mg/dl 2.Serum Triglyceride: 200-300 mg/dl 3.LDL Cholesterol: 100-150 mg/dl 4.HDL Cholesterol: 30-50 mg/dl 5.VLDL Cholesterol: 30-50 mg/dl

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1.Patients below 30 years and above 65 years of age. 2.Uncontrolled case of Type 2 Diabetes Mellitus. HbA1c > 7% 3.Arterial Stiffness Index (Severe Arterial Stiffness) 4.Patients on lipid-lowering drugs 5.Any co-morbid condition 6.Alcoholic 7.Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Improvement in Arterial Stiffness Index Arbitrary Scale for improvement in Arterial Stiffness Grade 0 No arterial stiffness Complete improvement Grade 1 Borderline arterial stiffness Partial improvement Grade 2 Mild arterial stiffness Slight improvement Grade 3 Moderate arterial stiffness No improvementTimepoint: Assessment of arterial stiffness through DRP at the initiation of treatment 0 day and at the end of the study 90th day—

Secondary

MeasureTime frame
Improvement in lipid parametersTimepoint: Lipid Profile at 0 30 and 90 days—

Countries

India

Contacts

Public ContactAzra Parveen

Ajmal Khan Tibbiya College, Aligarh Muslim University

tabassum94tariq@gmail.com8191916786

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026